These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34092620)

  • 1. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
    Wang Y; Zhao H; Zhao P; Wang X
    Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
    Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
    Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
    Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
    Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
    Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.
    Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y
    Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
    Lu WQ; Hu YY; Lin XP; Fan W
    Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma.
    Chen Z; Lu X; Wang Z; Jin G; Wang Q; Chen D; Chen T; Li J; Fan J; Cong W; Gao Q; He X
    Oncotarget; 2015 Feb; 6(4):2538-48. PubMed ID: 25576919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
    Li C; Zhao Z; Zhou Z; Liu R
    Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictive potential of Neuronatin for neoadjuvant chemotherapy of breast cancer.
    Pieper W; Ignatov A; Kalinski T; Haybaeck J; Czapiewski P; Nass N
    Cancer Biomark; 2021; 32(2):161-173. PubMed ID: 34092612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
    Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
    Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and clinical significance of pyruvate kinase M2 in breast cancer: A protocol for meta-analysis and bioinformatics validation analysis.
    Li H; Yan M; Wu X; Wang Y; Huang L
    Medicine (Baltimore); 2021 May; 100(18):e25545. PubMed ID: 33950928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
    Wang Y; Zhang X; Zhang Y; Zhu Y; Yuan C; Qi B; Zhang W; Wang D; Ding X; Wu H; Cheng J
    Cancer Biol Ther; 2015; 16(6):839-45. PubMed ID: 25970228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
    Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
    J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells.
    Yao A; Xiang Y; Si YR; Fan LJ; Li JP; Li H; Guo W; He HX; Liang XJ; Tan Y; Bao LY; Liao XH
    J Cell Biochem; 2019 Apr; 120(4):6542-6554. PubMed ID: 30368881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 20. Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.
    Lu W; Cao Y; Zhang Y; Li S; Gao J; Wang XA; Mu J; Hu YP; Jiang L; Dong P; Gong W; Liu Y
    Sci Rep; 2016 Jun; 6():26351. PubMed ID: 27283076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.